Compare TTRX & BSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTRX | BSL |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.9M | 169.3M |
| IPO Year | N/A | N/A |
| Metric | TTRX | BSL |
|---|---|---|
| Price | $5.99 | $12.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 58.2K | 42.5K |
| Earning Date | 05-31-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.55% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.57 | $12.45 |
| 52 Week High | $6.75 | $14.35 |
| Indicator | TTRX | BSL |
|---|---|---|
| Relative Strength Index (RSI) | 56.63 | 39.48 |
| Support Level | $4.70 | $12.82 |
| Resistance Level | $6.68 | $12.98 |
| Average True Range (ATR) | 0.56 | 0.08 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 53.36 | 36.36 |
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.